Mr. BENTSEN. Mr. Speaker, I rise today to honor the University of Texas M.D. Anderson Cancer Center on its 60th Anniversary on June 30, 2001. Although I will not be present at this Ceremony, I would like to honor this distinguished institution which is one of the world’s top tier of institutions devoted to the conquest of cancer.

Throughout its history, M.D. Anderson Cancer Center has set the standard for excellence in cancer patient care, research, education and prevention. Named for its benefactor, Monroe Dunaway Anderson, the hospital was designated one of the first three comprehensive cancer centers in the United States by the National Cancer Act of 1971, and has continued to be the model of other centers seeking such recognition. In 2000, M.D. Anderson was ranked by U.S. News & World Report magazine as the nation’s best cancer hospital. Since the first patient was registered in temporary quarters in 1944, nearly 500,000 people have been served at M.D. Anderson facilities in Houston, and patients everywhere have benefited from research-based discoveries made or inspired by the M.D. Anderson faculty and staff.

More than 40,000 physicians, scientists, nurses and health care professionals have trained at M.D. Anderson, where education is fully integrated with superb research, compassionate patient care and far-reaching cancer prevention programs.

Today, M.D. Anderson’s public education and community service initiatives help thousands of people reduce their risk of cancer and learn more about the disease.

The outstanding basic, translational and clinical research conducted at M.D. Anderson has been supported in recent years with the highest number of grants awarded to any institution by the National Cancer Institute and the American Cancer Society.

Translational research that applies new laboratory findings to improve patient treatments as quickly as possible has flourished under the leadership of Dr. John Mendelsohn, a distinguished clinical scientist who became M. D. Anderson’s President in 1996. Dr. Mendelsohn has recruited a visionary management team and established bold new priorities for M. D. Anderson in the 21st century.

Dr. John Mendelsohn is the third president of the institution. Dr. R. Lee Clark was named the first full-time director and surgeon-in-chief in 1946, two years after the first patient was admitted. Dr. Clark was succeeded by Dr. Charles A. LeMaistre, who was instrumental in recruiting many leading physicians and surgeons. Dr. Mendelsohn took over in 1996 after Dr. LeMaistre’s retirement.

Sixty years ago this month, a major research accomplishment made by M.D. Anderson scientists and physicians include: The first successful correction of a defective p53 tumor suppressor gene in human lung cancer has led to pioneering gene therapy for lung, head and neck, prostate, bladder and several other forms of cancer; Identification of the defective PTEN gene is providing new ways to target therapy for a usually fatal form of brain cancer and other malignant tumors;Expanded landmark chemoprevention studies showing that drugs can prevent first or second primary cancers in individuals at high risk—and also reverse some pre-malignant lesions; Designed a rapid laboratory method to pinpoint gene abnormalities in chromosomes, thereby improving diagnosis and treatment monitoring of many diseases, including cancer; Developed a gene expression technique to predict which cancers will escape primary sites and spread to other organs of the body; Identified genetic variants of components for a common brain chemical, dopamine, that are associated with nicotine addiction; Reported the first isolation of human malignant cells from normal blood cells with a technique that allows studying the intrinsic electrical properties of cells; Documented a molecular link between cigarettes and lung cancer from studies showing a carcinogen in tobacco smoke binds to key mutagenic sites in the p53 gene.

Over the years, M.D. Anderson has conducted extensive clinical trials that have led to more effective anti-cancer drugs and biologic compounds, less-invasive surgical procedures and more precise radiation techniques. Many standard cancer therapies now available around the world were originally evaluated, wholly or in part, through such clinical research studies at M.D. Anderson.

Research discoveries and inventions by M.D. Anderson faculty and staff have been responsible for important technology development partnerships with industry. Fifteen companies have been created as spinoffs from M.D. Anderson research projects.

While research advances at M.D. Anderson over the past 60 years have helped to slow the tide against cancer, the current outlook for better methods to diagnose, treat and, ultimately, prevent cancer is even more optimistic because of emerging knowledge about the